Shares of Repligen ( RGEN 0.26% ) jumped more than 16% this morning after the company reported third-quarter operating results. The company, which develops and sells equipment needed to manufacture and purify biologic drugs, delivered record quarterly revenue of $49.5 million and year-over-year growth of 35%. That prompted management to raise full-year 2018 revenue guidance to a midpoint of $192.5 million.